Skip to Content

Sanofi SA ADR SNY Stock Quote

| Rating as of


Morningstar‘s Stock Analysis SNY

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Sanofi Posts Strong Q3, Buoyed by Dupixent and Flu Vaccine Sales as Stock Looks Undervalued

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Sanofi reported strong third-quarter results ahead of our projections, but we don’t expect any major changes to our fair value estimate based on the outperformance, which was partly driven by earlier-than-expected flu vaccine sales. Nevertheless, we continue to view the stock as undervalued with the market not fully appreciating the long-term growth outlook for the firm supported by immunology drug Dupixent and new pipeline drugs that also support the firm’s wide moat. Additionally, we continue to view stock valuation loss earlier in the year surrounding concerns on potential Zantac litigation as excessive.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics SNY

Company Profile SNY

Business Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

54, Rue La Boetie
Paris, 75008, France
T +33 153774000
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 86,000

Related News SNY